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MeBACKGROUND The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54) trial studied
2 doses of ticagrelor, 90 mg twice a day (bid) and 60 mg bid, for long-term prevention of ischemic events in patients
with prior myocardial infarction. Both doses similarly reduced the rate of ischemic events versus placebo. The pharma-
cokinetics and pharmacodynamics of ticagrelor 60 mg bid have not been studied.
OBJECTIVES In this study, the authors sought to study the pharmacokinetics and pharmacodynamics for ticagrelor 60
mg compared with 90 mg bid.
METHODS A total of 180 patients who received >4 weeks of study medication had blood sampling in the morning
pre-maintenance dose and again 2 h post-dose. All patients received aspirin. Plasma levels of ticagrelor and its active
metabolite AR-C124910XX were determined. P2Y12 inhibition was assessed by the VerifyNow P2Y12 assay (Accumetrics,
Inc., San Diego, California) (P2Y12 reaction units [PRU]), light transmittance aggregometry (adenosine diphosphate 5 and
20 mmol/l and arachidonic acid), and vasodilator-stimulated phosphoprotein phosphorylation assays. VerifyNow Aspirin
assays and serum thromboxane B2 measurements were performed.
RESULTS Mean pre- and post-dose plasma levels of ticagrelor were 35% and 38% lower, respectively, with 60 mg
versus 90 mg. Both doses achieved high levels of platelet inhibition pre- and post-dose, with numerically slightly more
variability with 60 mg: mean (SD) pre-dose PRU values were 59  63 and 47  43 for ticagrelor 60 and 90 mg,
respectively (p ¼ 0.34). High platelet reactivity, determined as PRU >208, was rare with the 60-mg pre-dose and was
absent post-dose. Platelet reactivity pre- and post-dose, as measured by light transmittance aggregometry or
vasodilator-stimulated phosphoprotein assays, was numerically but not signiﬁcantly lower with 90 mg than with 60 mg.
Aspirin response was not affected by either dose.
CONCLUSIONS Ticagrelor 60 mg bid achieved high levels of peak and trough platelet inhibition in nearly all patients,
similar to that with 90 mg bid, helping to explain the efﬁcacy of the lower ticagrelor dose in PEGASUS-TIMI 54.
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ACS = acute coronary
syndrome
ADP = adenosine diphosphate
bid = twice a day
LTA = light transmittance
aggregometry
MI = myocardial infarction
PD = pharmacodynamic
PK = pharmacokinetic
PRI = platelet reactivity index
PRU = P2Y12 reaction units
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1146T icagrelor is a reversibly-bindingP2Y12 receptor antagonist that actsdirectly on platelet P2Y12 receptors
without requiring metabolic activation, al-
though its active metabolite AR-C124910XX
has similar potency at P2Y12 (1). The extent
of platelet P2Y12 inhibition, therefore, re-
ﬂects the plasma levels of ticagrelor and
AR-C124910XX, because platelet inhibition
recovers as these levels fall (2). Ticagrelor
at a maintenance dose of 90 mg twice a day
(bid) was shown to provide greater and
more consistent platelet P2Y12 inhibition
than clopidogrel in patients with stablecoronary artery disease (2) and acute coronary syn-
dromes (ACS) (3,4). The PLATO (Platelet Inhibition
and Patient Outcomes) trial demonstrated the supe-
rior efﬁcacy of ticagrelor, given at a maintenance
dose of 90 mg bid, compared with clopidogrel for up
to 1 year in patients with ACS (5). Consequently, this
regimen of ticagrelor is recommended in interna-
tional guidelines as ﬁrst-line therapy for up to 1 year
following either non–ST-segment elevation ACS (6,7)
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TABLE 1 Demographic Characteristics at Randomization and Medication at
the Time of Blood Sampling After More Than 28 Days of Study Drug
Placebo
(n ¼ 64)
Ticagrelor
60 mg
(n ¼ 58)
Ticagrelor
90 mg
(n ¼ 58)
Age, yrs 64.2  6.6 63.3  6.6 64.2  6.9
Female 14 (22) 5 (9) 10 (17)
Body weight, kg 86 (75–98) 86 (76–100) 81 (71–94)
Body mass index, kg/m2 29.7  4.8 30  5.6 28.6  5.0
Race
White 60 (94) 53 (91) 55 (95)
Black 4 (6) 5 (9) 3 (5)
Asian or other 0 (0) 0 (0) 0 (0)
Prior MI diagnosis
Years since MI 1.7 (1.2–2.1) 1.7 (1.4–2.2) 1.8 (1.4–2.2)
STEMI 37 (58) 30 (52) 29 (50)
NSTEMI 27 (42) 28 (48) 28 (48)
Not known 0 (0) 0 (0) 1 (2)
Cardiovascular risk factors
Current smoker 8 (13) 9 (16) 11 (19)
Diabetes mellitus 18 (28) 20 (35) 12 (21)
Hypertension 37 (58) 26 (45) 30 (52)
Multivessel CAD 41 (64) 37 (64) 32 (55)
Peripheral arterial disease 2 (3) 4 (7) 0 (0)
Creatinine clearance <60 ml/min 6 (9) 5 (9) 9 (16)
Time since last dose of study
medication, pre-dose, h
12 (11–13) 12 (11–13) 12 (11–13)
Concomitant medication
Aspirin 75 or 81 mg daily 64 (100) 58 (100) 58 (100)
Beta-blockers 59 (92) 48 (83) 53 (91)
Statins 61 (95) 56 (97) 55 (95)
ACE inhibitors or ARBs 60 (94) 52 (90) 52 (90)
Values are mean  SD, n (%), or median (interquartile range). All comparisons between the
groups are not signiﬁcant.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CAD ¼ coronary
artery disease; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; STEMI ¼ ST-segment elevation myocardial infarction.
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1147In PEGASUS-TIMI 54, both doses of ticagrelor
had similar efﬁcacy and safety compared with
placebo: hazard ratios for the primary efﬁcacy
endpoint (the composite of cardiovascular death,
MI, or stroke) were 0.85 (95% conﬁdence interval
[CI]: 0.75 to 0.96) and 0.84 (95% CI: 0.74 to 0.95)
and for the primary safety endpoint (TIMI
[Thrombolysis In Myocardial Infarction] major
bleeding) were 2.69 (95% CI: 1.96 to 3.70) and 2.32
(95% CI: 1.68 to 3.21) for ticagrelor 90 and 60 mg
bid, respectively (11). We performed a substudy in
patients enrolled in PEGASUS-TIMI 54 to study the
PK and PD effects of ticagrelor 60 mg bid and
compare these with the effects of ticagrelor
90 mg bid.
METHODS
STUDY DESIGN. A total of 180 patients who were
taking part in the PEGASUS-TIMI 54 study provided
additional consent to take part in this substudy,
which was conducted at 4 centers: 3 in the United
Kingdom (Shefﬁeld, Rotherham, and Nottingham)
and 1 in the United States (Jacksonville, Florida). The
substudy was conducted according to a protocol
approved by the relevant ethics committee and
institutional review board. Patients were studied af-
ter they had received study medication for at least 4
weeks following randomization in a 1:1:1 fashion to
receive placebo, ticagrelor 60 mg bid, or ticagrelor
90 mg bid. Patients attended in the morning for
their substudy visit, having taken their last dose of
scheduled study medication the evening before.
Venous blood was collected by venipuncture, then
the morning dose of study medication was adminis-
tered, and further venous blood was collected 2 h
later. PK and PD analyses were performed as
described in the following sections.
PK STUDIES. Venous blood was collected into lithium
heparin tubes and placed on ice prior to centrifuga-
tion at 1,500 g within 30 min. Plasma was transferred
to a polypropylene tube and immediately frozen
at 20C before being shipped to Covance Central
Laboratories (Indianapolis, Indiana) for analysis of
ticagrelor and AR-C124910XX levels (12). The lower
limits of detection of the assays are 1 ng/ml for tica-
grelor and 2.5 ng/ml for AR-C124910XX.
VERIFYNOW P2Y12 AND ASPIRIN ASSAYS. Venous
blood was collected into 2-ml citrate Vacutainers and
analyzed using the VerifyNow P2Y12 and Aspirin as-
says (Accumetrics, Inc., San Diego, California) ac-
cording to the manufacturer’s instructions (4). For the
P2Y12 assay, P2Y12 reaction units (PRU) and percentage
inhibition (derived from the simulated baselineresponse induced by thrombin receptor-activating
peptide) were recorded. The aspirin assay was per-
formed in a subset of patients and aspirin response
units were recorded.
LIGHT TRANSMITTANCE AGGREGOMETRY. Light
transmittance aggregometry (LTA) was performed us-
ing a Chrono-log (Havertown, Pennsylvania) aggreg-
ometer, and adenosine diphosphate (ADP) (5 and
20 mmol/l) and arachidonic acid (1 mmol/l; performed
post-dose in a subset of patients) as agonists (3).
Maximum percentage LTA responses were recorded.
VASODILATOR-STIMULATED PHOSPHOPROTEIN
PHOSPHORYLATION ASSAY. Aliquots of whole blood
were processed using a vasodilator-stimulated phos-
phoprotein phosphorylation assay kit, and platelet
reactivity index (PRI) was determined according to
the manufacturer’s instructions (BioCytex, Marseille,
France) (4).
FIGURE 1 Plasma Levels of Ticagrelor and its Active Metabolite
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Mean levels of (A) ticagrelor and (B) AR-C124910XX in the ticagrelor 60-mg bid group
(n ¼ 57 to 58) and ticagrelor 90-mg bid group (n ¼ 56 to 57). Error bars indicate SD.
***p # 0.0001. bid ¼ twice a day.
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1148SERUM THROMBOXANE B2. Venous blood was
added to a serum separator tube (Becton Dickinson,
Oxford, United Kingdom) and incubated at 37C for
30 min followed by centrifugation at 1,000 g for
15 min. The supernatant serum was then trans-
ferred to cryovials and was stored at 80C prior
to analysis. Thromboxane B2 levels were measured
by an ELISA kit (Cayman Chemicals, Ann Arbor,
Michigan).
SAMPLE SIZE AND STATISTICAL ANALYSIS. On the
basis of expected mean pre-dose PRU values in the
ticagrelor 90-mg group of 79 PRU and SD of 78 PRU
(4), 57 patients were required in each ticagrelor group
to provide 80% power to detect a mean pre-dose PRU
value in the ticagrelor 60-mg group that was 50 PRU
higher than for the 90-mg group with an alpha of
0.01. A total of 180 patients were included to allowfor expected imbalance in the ﬁnal numbers in each
of the 3 groups.
Data were analyzed using SAS version 9.3 (SAS
Institute, Cary, North Carolina) and expressed as
mean and SD or median and interquartile range, as
indicated. Continuous data for the placebo and tica-
grelor groups were compared using the Kruskal-
Wallis test. Categorical variables were compared
using the Fisher exact test. Statistical signiﬁcance
was attached to p values <0.01 to allow for multiple
group comparisons.
The proportion of patients in each treatment group
with responses greater than thresholds previously
associated with increased ischemic risk (“high platelet
reactivity”) (13) were determined as follows: Verify-
Now P2Y12 assay result >208 PRU (14,15); maximum
LTA response to ADP 20 mmol/l >59% (16–18);
maximum LTA response to ADP 5 mmol/l >46% (17,18);
PRI >50% (18,19); VerifyNow aspirin response units
>550 (20,21); and maximum LTA response to arach-
idonic acid $20% (22,23).
RESULTS
STUDY POPULATION. A total of 180 patients were
studied after at least 4 weeks of maintenance treat-
ment with placebo (n ¼ 64), ticagrelor 60 mg bid
(n ¼ 58), or ticagrelor 90 mg bid (n ¼ 58). De-
mographic characteristics and comedications were
generally well matched in the 3 treatment arms
(Table 1). All patients were receiving low-dose aspirin.
The baseline characteristics of the substudy patients
versus the entire trial cohort are shown in Online
Table 1.
PK RESULTS. Mean pre- and post-dose plasma tica-
grelor levels in the 60-mg group were 65% and 62% of
those in the 90-mg group, respectively, and mean
pre- and post-dose plasma AR-C124910XX levels in
the 60-mg group were both 54% of those in the 90-mg
group (Figure 1).
MEASURES OF PLATELET P2Y12 INHIBITION. All
measures of P2Y12-mediated platelet reactivity
showed numerically (but not statistically signiﬁ-
cantly) greater platelet inhibition with ticagrelor 90
mg bid compared with ticagrelor 60 mg bid, both pre-
and post-dose (Central Illustration, Figures 2 to 4,
Online Table 2). VerifyNow P2Y12 assay results
showed high mean levels of platelet inhibition in both
ticagrelor groups, but a slightly greater SD with the
60 mg bid regimen (Central Illustration, Figure 2,
Online Table 2): mean pre-dose PRU values were
59  63 PRU versus 47  43 PRU for the 60 mg
versus 90 mg ticagrelor doses, and post-dose values
were 29  39 PRU versus 20  19 PRU, respectively.
CENTRAL ILLUSTRATION Platelet Inhibition With Ticagrelor 60 mg Compared With 90 mg Twice Daily:
VerifyNow P2Y12 Assay Results
PRU = 208
Pl
at
el
et
 R
ea
ct
io
n 
Un
its
 (P
RU
)
Placebo         Ticagrelor       Ticagrelor         Placebo        Ticagrelor        Ticagrelor
60mg              90mg                                       60mg              90mg
400 p = 0.73
300
p = 0.34
200
100
0
Storey, R.F. et al. J Am Coll Cardiol. 2016; 67(10):1145–54.
Individual results for the VerifyNow P2Y12 assay (Accumetrics, Inc., San Diego, California) expressed as P2Y12 reaction units (PRU). The dashed line indicates a level
of 208 PRU as a threshold for high platelet reactivity. Solid lines with error bars indicate mean  SD. There are no signiﬁcant differences between the ticagrelor groups
(all p > 0.01).
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1149Similarly, mean LTA responses to ADP (Figure 3)
and mean PRI levels (Figure 4) were low in both
ticagrelor groups compared with the placebo group
at both pre- and post-dose. The VerifyNow P2Y12
percent inhibition estimation provided the greatest
separation between placebo group and ticagrelor
group values (Figure 2).
HIGH P2Y12-MEDIATED PLATELET REACTIVITY.
Overall, high platelet reactivity with the measures of
P2Y12 inhibition was uncommon (Central Illustration,
Figures 3 and 4, Table 2). With the VerifyNow P2Y12
assay, only 2 patients in the ticagrelor 60-mg grouphad PRU values >208 pre-dose (3.5%), and there were
no other instances of high platelet reactivity (Central
Illustration). One of these patients also had high
platelet reactivity to ADP as determined by LTA, and
both had high platelet reactivity as determined by
vasodilator-stimulated phosphoprotein phosphoryla-
tion assay. The patient with a pre-dose PRU value of
369 (0% inhibition) had PK levels of both ticagrelor
and AR-C124910XX that were below the limits of
detection, indicating poor compliance, and this pa-
tient’s post-dose value was 122 PRU (69% inhibition).
Another patient with a pre-dose PRU value of 211
(17% inhibition) also had low PK levels of ticagrelor
FIGURE 2 VerifyNow P2Y12 Assay % Inhibition Results
100
80
60
40
20
0
Placebo Ticagrelor
60mg
Ticagrelor
90mg
Pre-dose
Placebo Ticagrelor
60mg
Ticagrelor
90mg
Post-dose
Ve
rif
yN
ow
 %
 In
hi
bi
tio
n
P = 0.34 P = 0.59
% inhibition
Individual results for the VerifyNow P2Y12 assay (Accumetrics, Inc., San Diego, California) expressed as percentage inhibition derived from an
estimated “baseline” response using thrombin receptor-activating peptide as agonist. Solid lines with error bars indicate mean  SD. There are
no signiﬁcant differences between the ticagrelor groups (all p > 0.01).
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1150(40 ng/ml) and AR-C124910XX (18 ng/ml) and had a
post-dose value of 39 PRU (86% inhibition).
There were few cases of high platelet reactivity in
either ticagrelor group according to either LTA re-
sponses to ADP or PRI levels (Figures 3 and 4, Table 2).
MEASURES OF ASPIRIN RESPONSE. VerifyNow
Aspirin response assay, LTA with arachidonic acid as
agonist, and serum thromboxane B2 levels all indi-
cated high levels of cyclooxygenase-1 inhibition by
aspirin in nearly all patients, with few patients having
high platelet reactivity to arachidonic acid in each of
the treatment groups pre- and post-ticagrelor dose
(Online Figure 1, Online Table 3). There were no sig-
niﬁcant differences between the placebo group and
either of the ticagrelor groups.
DISCUSSION
This PEGASUS-TIMI 54 substudy is the ﬁrst assess-
ment of the PK and PD effects of the ticagrelor 60 mg
bid regimen. The PK results showed levels of tica-
grelor in the 60-mg group at approximately two-
thirds of the ticagrelor levels in the 90-mg group,as expected on the basis of previous PK studies.
Most intriguing was the similar mean platelet P2Y12
inhibition achieved with ticagrelor 60 and 90 mg bid.
This was unexpected, as it had been intended to
achieve a lower level of platelet inhibition with the
60-mg regimen (10), but the observed similarity in
platelet inhibition between the 2 ticagrelor groups is
entirely consistent with the efﬁcacy results in the
main trial being almost identical with ticagrelor 60
and 90 mg bid compared with placebo (11). Indeed,
only 2 patients in the ticagrelor 60-mg group had high
platelet reactivity pre-dose, according to the Ver-
ifyNow P2Y12 assay, and both of these patients had
excellent inhibition post-dose. Furthermore, 1 of
these patients had evidence of poor compliance with
study medication. The tolerability of the 60-mg bid
regimen is slightly better than with the 90-mg bid
regimen: the frequency of dyspnea adverse events
related to ticagrelor is moderately associated with
dose and PK levels (24–27), and the rates of dyspnea
were numerically lower with ticagrelor 60 mg bid
compared with ticagrelor 90 mg bid in PEGASUS-TIMI
54 (11). In addition, the rates of bleeding, transfusion,
FIGURE 3 ADP-Induced Platelet Aggregation
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Individual results for the platelet aggregation measured by light transmittance aggregometry and assessing maximum aggregation response to
(A) ADP 20 mmol/l and (B) ADP 5 mmol/l. The dashed lines indicate threshold values for high platelet reactivity. Solid lines with error bars
indicate mean  SD. There are no signiﬁcant differences between the ticagrelor groups (all p > 0.01). ADP ¼ adenosine diphosphate.
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1151and gout were numerically lower with ticagrelor
60 mg bid compared with ticagrelor 90 mg bid in
PEGASUS-TIMI 54. Our results therefore support the
preferential use of ticagrelor 60 mg bid instead of
90 mg bid in patients with good adherence to anti-
platelet medication who are more than 1 year post-MI.
This approach has been endorsed by the recent Food
and Drug Administration approval of ticagrelor 60 mg
bid for long-term use following MI (28). Furthermore,a therapeutic trial of the 60-mg ticagrelor dose might
be considered prior to 1 year post-MI for those who
cannot tolerate the 90-mg dose due to dyspnea or
minor bleeding.
We observed no effect of ticagrelor on the mea-
surements of aspirin response, suggesting that, at
least in aspirin-treated patients, P2Y12 inhibition does
not signiﬁcantly inﬂuence release of the platelet
agonist thromboxane A2 (because PD measures of
FIGURE 4 VASP Phosphorylation Assay Results
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Individual results for the VASP phosphorylation assay. The dashed line indicates the threshold value of 50% for high platelet reactivity. Solid
lines with error bars indicate mean  SD. There are no signiﬁcant differences between the ticagrelor groups (all p > 0.01). PRI ¼ platelet
reactivity index; VASP ¼ vasodilator-stimulated phosphoprotein.
TABLE 2 Proportion
According to Pre-Deﬁ
Measures of P2Y12 Inhib
VerifyNow P2Y12 assay
Pre-dose, PRU >208
Post-dose, PRU >20
VASP assay
Pre-dose, PRI >50%
Post-dose, PRI >50%
LTA, 20 mmol/l ADP
Pre-dose, aggregatio
Post-dose, aggregati
LTA, 5 mmol/l ADP
Pre-dose, aggregatio
Post-dose, aggregati
Sample size is the number
above the given threshold
ADP ¼ adenosine diphos
reaction units; VASP ¼ vas
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1152aspirin response reﬂect conversion of arachidonic
acid into thromboxane A2). This raises a note of
caution about dropping aspirin when treating with
ticagrelor alone if there is a high thrombotic risk ands of Patients With High P2Y12-Mediated Platelet Reactivity
ned Threshold Values
ition
Ticagrelor 60 mg Ticagrelor 90 mg p Value
90 mg vs.
60 mgSample Size Proportion Sample Size Proportion
57 2 (4) 55 0 (0) 0.50
8 55 0 (0) 58 0 (0) N/A
57 3 (5) 58 3 (5) 1.0
56 5 (9) 58 1 (2) 0.11
n >59% 56 2 (4) 57 2 (4) 1.0
on >59% 54 0 (0) 57 2 (4) 0.50
n >46% 56 1 (2) 57 1 (2) 1.0
on >46% 54 1 (2) 57 0 (0) 0.49
of patients with available data in each group. Proportion is the number with values
value, given as n (%) (percent is calculated as: [sample size/proportion]  100).
phate; LTA ¼ light transmittance aggregometry; N/A ¼ not applicable; PRU ¼ P2Y12
odilator-stimulated phosphoprotein.emphasizes the importance of waiting for the results
of adequately powered clinical outcomes studies of
ticagrelor monotherapy compared with dual anti-
platelet therapy.
STUDY LIMITATIONS. This PK/PD substudy was not
large enough to allow assessment of the relationship
between platelet function results and clinical out-
comes. We did not assess the effects of the 2 tica-
grelor regimens on adenosine reuptake, and so
cannot exclude a signiﬁcant difference between the 2
ticagrelor regimens on plasma adenosine levels,
which may also contribute to platelet inhibition
in vivo (29,30); this is being assessed in a further
study of patients undergoing elective percutaneous
coronary intervention (NCT02327624). We also did
not assess baseline platelet reactivity prior to initia-
tion of study medication; we relied on the VerifyNow
P2Y12 assay estimate of inhibition, using thrombin
receptor activating peptide-induced response to give
a predicted baseline response, rather than deriving
inhibition data from pre-treatment platelet re-
sponses. The substudy did not include Asian patients
and had limited numbers of low body weight patients
(<60 kg), so further PK/PD studies are required to
assess these groups.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with prior MI receiving extended dual anti-
platelet therapy, ticagrelor 60 mg bid provides a degree of
platelet inhibition comparable to that achieved with 90 mg bid.
This may explain the nearly equivalent efﬁcacy of these doses for
prevention of recurrent ischemic events.
TRANSLATIONAL OUTLOOK: These observations call for
further investigation of the safety and efﬁcacy of 60-mg bid
dosing of ticagrelor in other clinical settings associated with
atherothrombosis.
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1153CONCLUSIONS
We have shown that ticagrelor 60 mg bid achieves
high levels of peak and trough platelet inhibition in
patients with a prior history of MI, with similar
mean levels of inhibition compared with 90 mg
bid. These results help to explain the comparable
efﬁcacy of the lower ticagrelor dose in the
PEGASUS-TIMI 54 study.
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